Inari Medical today announced it launched two new catheters for venous stent thrombosis and venous thromboembolism. The Irvine, California-based company launched its RevCore thrombectomy catheter and the Triever16 Curve catheter. RevCore is a mechanical thrombectomy device for venous in-stent thrombosis, and Triever16 Curve is for pulmonary embolism and peripheral thrombectomy. “We are thrilled to announce […]
Inari Medical
Analysts are bullish on Inari Medical following Q4 results
Inari Medical (Nasdaq:NARI) shares dipped today despite fourth-quarter results that left analysts excited for the coming year. Shares of NARI fell 3.5% at $55.34 apiece in midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up slightly. The Irvine, California-based thrombectomy device developer posted losses of […]
Inari Medical enrolls first patient in ClotTriever system trial for treating deep vein thrombosis
Inari Medical (Nasdaq:NARI) today announced that it enrolled the first patient in its Defiance trial for evaluating the ClotTriever system. In August 2022, Inari Medical announced the launch of its Defiance trial for comparing ClotTriever to anticoagulation. Those enrolled in the trial (300 patients total) only have iliofemoral deep vein thrombosis (DVT). The trial spans […]
Inari Medical rises on Street-beating Q3, increased guidance
Inari Medical (Nasdaq:NARI) shares ticked up after hours today on third-quarter results that topped the consensus forecast. The Irvine, California-based thrombectomy device developer posted losses of $10.2 million. That equals 19¢ per share on sales of $96.2 million for the three months ended Sept. 30, 2022. Inari registered a more than $7 million bottom-line deeper […]
Inari Medical reports positive outcomes from FlowTriever study
Inari Medical (Nasdaq:NARI) announced today that the FLASH registry evaluating its FlowTriever produced positive results. The company designed its FlowTriever for device retrieval and aspiration. The system treats pulmonary embolism (PE). FlowTriever non-surgically removes clots from peripheral blood vessels. Its uses include treatment for PE and clots in transit in the right atrium. It received […]
Inari Medical launches trial to assess ClotTriever system in deep vein thrombosis
Inari Medical (Nasdaq:NARI) announced that it will conduct a trial for its ClotTriever system for iliofemoral deep vein thrombosis (DVT). The Irvine, California-based company’s Defiance trial will compare ClotTriever to anticoagulation only for patients with iliofemoral DVT. Defiance will enroll 300 patients across up to 60 centers around the world. It represents Inari’s second randomized […]
Inari Medical to promote COO into CEO spot
Inari Medical (Nasdaq:NARI) announced this week that Drew Hykes will succeed Bill Hoffman as the company’s CEO. Hykes, who currently serves as COO at the venous-specific devices company, will succeed Hoffman, effective Jan. 1, 2023. He will also join Inari’s board, while Hoffman will continue to serve on the board as well. “Drew is a […]
Inari Medical to bring in up to $186.3M in stock offering
Inari Medical (Nasdaq:NARI) announced that it priced an underwritten public offering worth up to $186.3 million in proceeds. Irvine, California-based Inari Medical’s offering includes 2 million shares of its common stock at a public offering price of $81 per share before underwriting discounts and commissions. In addition, the company granted the underwriters a 30-day option […]
Inari Medical to raise $156m in upsized IPO
Inari Medical (NSDQ:NARI) announced that it upsized its initial public offering of common stock shares for total gross proceeds of approximately $156 million. Earlier this week, the venous disease treatment developer announced that it launched the roadshow for its initial public offering (IPO) of shares of its common stock, planning to offer more than 7.3 million […]
Inari Medical plans to launch IPO to raise more than $110m
Inari Medical announced today that it launched the roadshow for its initial public offering (IPO) of shares of its common stock. The venous disease treatment developer is offering more than 7.3 million shares of common stock with an expected additional 30-day option for underwriters to purchase close to 1.1 million more shares. Irvine, Calif.-based Inari […]
Cutera snags Vyaire Medical’s Mowry for CEO | Personnel Moves, July 9, 2019
Cutera (NSDQ:CUTR) said today that it snagged Vyaire Medical CEO David Mowry to be its new CEO, effective immediately. The aesthetic device maker in January fired president & CEO James Reinstein after the company missed expectations for its 2018 top line, naming COO Jason Richey as interim chief executive. Mowry led Tornier to a $3.3 billion […]
